ERBB2 and breast cancer: Our DFS findings were in line with the 3-year rates of 0.87 and 0.89 for patients with HER2-positive early breast cancer treated with trastuzumab for 1 or 2 years, respectively, in the phase III HERA trial, which enrolled patients who had undergone diverse primary treatment (including surgery, neoadjuvant chemotherapy, adjuvant chemotherapy, and radiation therapy) [17].